EB病毒阳性弥漫大B细胞淋巴瘤的特点及新药时代治疗进展

Characteristics of Epstein-Barr virus-positive diffuse large B-cell lymphoma and the treatment progress in the era of new drugs

EB病毒(EBV)阳性弥漫大B细胞淋巴瘤-非特指型(DLBCL-NOS)是一种与慢性EBV感染相关的侵袭性B细胞淋巴瘤,其细胞的胞核中表达EBV编码RNA(EBER),在2016年版世界卫生组织淋巴瘤分类中将其列为单独实体。该淋巴瘤发病以老年人居多,免疫化疗效果差,总生存时间短,这种较差的预后与国际预后指数(IPI)分层不一致。CD30、程序性死亡受体1及其配体1有望成为预后指标和治疗靶点。文章对EBV+DLBCL-NOS与EBV感染的关系、临床病理特征、预后评估因素及新药时代的治疗进行综述。

Epstein-Barr virus(EBV)-positive diffuse large B-cell lymphoma,not otherwise specified(DLBCL-NOS),an aggressive B-cell lymphoma associated with chronic EBV infection,is an entity included in 2016 World Health Organization classification of lymphoid neoplasms.EBV-coding RNA(EBER)is expressed in the nucleus of these tumor cells.EBV-positive DLBCL can be mostly found in the elderly who have poor immunochemotherapy effect and short overall survival time,and this poor prognosis is inconsistent with international prognostic index(IPI)stratification.CD30 and programmed death 1/programmed death ligand 1 are expected to be the potential prognostic indicators and therapeutic targets.This paper reviews the relationship between EBV-positive DLBCL-NOS and EBV infection,clinicopathological characteristics,prognostic evaluation factors and treatment in the era of new drugs.